Direct oral anticoagulants for stroke prevention in device-detected AF

Area of Science:

• Cardiology
• Neurology
• Clinical Trials

Background:

• Device-detected atrial fibrillation (DDAF) is common in patients with cardiovascular implantable electronic devices.
• The optimal antithrombotic strategy for stroke prevention in DDAF remains uncertain.
• Previous trials have yielded conflicting results regarding anticoagulation efficacy in DDAF.

Purpose of the Study:

• To evaluate the efficacy and safety of direct oral anticoagulants (DOACs) for stroke prevention in patients with DDAF.
• To conduct a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials.
• To inform clinical practice guidelines for managing DDAF.

Main Methods:

• Study-level meta-analysis combining individual patient data from the NOAH-AFNET 6 and ARTESiA trials.
• Inclusion of patients with DDAF randomized to DOACs or antiplatelet therapy/placebo.
• Primary outcome: composite of stroke or systemic embolism; secondary outcomes: major bleeding.

Main Results:

• DOACs did not significantly reduce the risk of stroke or systemic embolism compared to control.
• The rate of major bleeding was significantly higher in patients treated with DOACs.
• No significant difference in all-cause mortality was observed between treatment groups.

Conclusions:

• DOACs are not effective for stroke prevention in patients with DDAF.
• Current guidelines recommending against anticoagulation in DDAF are supported by these findings.
• Risk of bleeding outweighs potential benefits of DOACs in this patient population.